UK markets close in 2 hours 20 minutes
  • FTSE 100

    7,102.85
    +28.79 (+0.41%)
     
  • FTSE 250

    22,581.21
    -78.21 (-0.35%)
     
  • AIM

    1,236.98
    +5.89 (+0.48%)
     
  • GBP/EUR

    1.1647
    -0.0055 (-0.47%)
     
  • GBP/USD

    1.3922
    -0.0041 (-0.30%)
     
  • BTC-GBP

    24,345.14
    -440.66 (-1.78%)
     
  • CMC Crypto 200

    816.91
    +6.72 (+0.83%)
     
  • S&P 500

    4,241.84
    -4.60 (-0.11%)
     
  • DOW

    33,874.24
    -71.34 (-0.21%)
     
  • CRUDE OIL

    72.65
    -0.43 (-0.59%)
     
  • GOLD FUTURES

    1,783.30
    -0.10 (-0.01%)
     
  • NIKKEI 225

    28,875.23
    +0.34 (+0.00%)
     
  • HANG SENG

    28,882.46
    +65.39 (+0.23%)
     
  • DAX

    15,559.31
    +102.92 (+0.67%)
     
  • CAC 40

    6,611.14
    +60.07 (+0.92%)
     

Freshfields Reinforces Position as Preeminent Life Sciences Law Firm With Addition of Adam H. Golden as Partner

·3-min read

In a move that reinforces its position as the preeminent life sciences law firm, Freshfields Bruckhaus Deringer LLP announced today that Adam H. Golden, market-leading life sciences transactions lawyer, has joined the firm as a partner in New York.

Mr. Golden brings extensive experience advising pharmaceutical, biotech and medical device companies and investors on license and collaboration deals, M&A, financings and commercial transactions. His arrival responds to the demand from Freshfields clients across the life sciences spectrum for support on their most strategic initiatives. As head of U.S. life sciences transactions for the firm, Mr. Golden further bolsters Freshfields’ commitment to support life sciences clients with lawyers who deeply understand the sector and its business requirements.

"Adam brings a wealth of experience and skill in critical areas for our life sciences clients," said Jennifer Bethlehem, partner and global head of Freshfields’ healthcare practice. "His work lies at the heart of what life sciences companies are doing every day to advance their business strategies, making him a valuable resource for our clients and an important member of our team."

Notable matters handled by Mr. Golden include pivotal licensing and collaboration projects on behalf of Novartis, Gilead Sciences and Celgene; Novartis’s $8.7bn acquisition of AveXis; and Celgene’s $9bn acquisition of Juno Therapeutics and acquisition of Impact Biomedicines for up to $7bn.

Mr. Golden is recognized as a leading life sciences transactions lawyer in Chambers Global, Chambers USA, Legal 500 US, Who's Who Legal, LMG Life Sciences, IFLR1000 and IAM Patent 1000. He has been named as an M&A Attorney of the Year and Life Sciences Star by LMG Life Sciences, and a Life Sciences MVP by Law360.

John Fisher, who heads up the firm’s life sciences and technology M&A practice in the U.S. and co-founded the firm’s Silicon Valley office, added, "Adam is an outstanding and well-known practitioner in the life sciences space who adds further depth to our team and will serve as a key resource for our clients at all stages of growth across the country."

"I am excited to join the outstanding Freshfields team and contribute to the growth of the life sciences practice in the U.S. and globally. I look forward to collaborating with my new colleagues to offer sophisticated advice, based on a deep understanding of the industry, to help our clients achieve their business objectives," said Mr. Golden.

About Freshfields Bruckhaus Deringer LLP

Freshfields Bruckhaus Deringer LLP is a global elite law firm with a long-standing track record of successfully supporting the world's leading national and multinational corporations, financial institutions and governments on groundbreaking and business-critical mandates. Our 2,800-plus lawyers deliver results worldwide through our own offices and alongside leading local firms. Our commitment, local and multinational expertise, and business know-how means our clients rely on us when it matters most.

Freshfields is ranked by Chambers Global in Band 1 across the six areas of antitrust, corporate/M&A, litigation, international arbitration, tax, and public international law. For more information visit Freshfields.us.

This material is for general information only and is not intended to provide legal advice. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005653/en/

Contacts

Elliott Frieder
elliott.frieder@freshfields.com
Mobile: +1 973 760 7400
Office: +1 212 230 4664

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting